IL303518A - Mutations orthogonal to heterodimerization - Google Patents
Mutations orthogonal to heterodimerizationInfo
- Publication number
- IL303518A IL303518A IL303518A IL30351823A IL303518A IL 303518 A IL303518 A IL 303518A IL 303518 A IL303518 A IL 303518A IL 30351823 A IL30351823 A IL 30351823A IL 303518 A IL303518 A IL 303518A
- Authority
- IL
- Israel
- Prior art keywords
- domain
- amino acid
- sequence
- domains
- mutation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063123915P | 2020-12-10 | 2020-12-10 | |
| PCT/US2021/062951 WO2022125986A1 (en) | 2020-12-10 | 2021-12-10 | Orthogonal mutations for heterodimerization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL303518A true IL303518A (en) | 2023-08-01 |
Family
ID=81974005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL303518A IL303518A (en) | 2020-12-10 | 2021-12-10 | Mutations orthogonal to heterodimerization |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12312418B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4259194A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024500354A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230118612A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116867514A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021397322A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3207821A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303518A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006899A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022125986A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023245021A2 (en) * | 2022-06-14 | 2023-12-21 | Invenra Inc. | Multispecific binding agents that target cd25 and/or ctla4 and uses thereof |
| WO2025129132A1 (en) * | 2023-12-14 | 2025-06-19 | Invenra Inc. | Multispecific binding agents that target ctla4 and/or cd25 and uses thereof |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013537416A (ja) * | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | 変異型Fc領域を含むモノマーポリペプチド及び使用方法 |
| CN103429620B (zh) * | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| EA032681B1 (ru) * | 2012-11-27 | 2019-07-31 | Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн | ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ |
| SG11201506451UA (en) * | 2013-03-06 | 2015-09-29 | Merrimack Pharmaceuticals Inc | Anti-c-met tandem fc bispecific antibodies |
| JP6724023B2 (ja) * | 2015-02-09 | 2020-07-15 | リサーチ ディベロップメント ファウンデーション | 改善された補体活性化を示す操作された免疫グロブリンfcポリペプチド |
| EP3511340B1 (en) * | 2016-08-10 | 2024-10-02 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same |
| DK3529269T3 (da) * | 2016-10-19 | 2026-02-23 | Invenra Inc | Antistof-konstruktioner |
| US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
| IL274071B2 (en) * | 2017-10-30 | 2025-10-01 | Hoffmann La Roche | Method for generating in vivo multispecific antibodies from monospecific antibodies |
| WO2019204522A1 (en) * | 2018-04-17 | 2019-10-24 | Invenra Inc. | Binding molecules |
| PE20210320A1 (es) * | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
| JP7812230B2 (ja) * | 2019-04-25 | 2026-02-09 | エフ. ホフマン-ラ ロシュ アーゲー | ポリペプチド鎖交換による抗体由来ポリペプチドの生成 |
| MX2022010176A (es) * | 2020-02-20 | 2023-01-16 | Win Therapeutics Inc | Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso. |
-
2021
- 2021-12-10 MX MX2023006899A patent/MX2023006899A/es unknown
- 2021-12-10 AU AU2021397322A patent/AU2021397322A1/en active Pending
- 2021-12-10 JP JP2023535392A patent/JP2024500354A/ja active Pending
- 2021-12-10 IL IL303518A patent/IL303518A/en unknown
- 2021-12-10 WO PCT/US2021/062951 patent/WO2022125986A1/en not_active Ceased
- 2021-12-10 CN CN202180091688.7A patent/CN116867514A/zh active Pending
- 2021-12-10 US US17/548,375 patent/US12312418B2/en active Active
- 2021-12-10 KR KR1020237022864A patent/KR20230118612A/ko active Pending
- 2021-12-10 CA CA3207821A patent/CA3207821A1/en active Pending
- 2021-12-10 EP EP21904522.6A patent/EP4259194A4/en active Pending
-
2025
- 2025-04-25 US US19/190,527 patent/US20260078202A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024500354A (ja) | 2024-01-09 |
| US12312418B2 (en) | 2025-05-27 |
| US20260078202A1 (en) | 2026-03-19 |
| CA3207821A1 (en) | 2022-06-16 |
| EP4259194A1 (en) | 2023-10-18 |
| MX2023006899A (es) | 2023-09-04 |
| US20220363782A1 (en) | 2022-11-17 |
| AU2021397322A1 (en) | 2023-07-06 |
| AU2021397322A9 (en) | 2024-06-20 |
| CN116867514A (zh) | 2023-10-10 |
| EP4259194A4 (en) | 2025-03-19 |
| WO2022125986A1 (en) | 2022-06-16 |
| KR20230118612A (ko) | 2023-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6385357B2 (ja) | 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するch3ドメイン変異体対、その作製方法および用途 | |
| IL322472A (en) | Humanized antibodies against c-kit | |
| IL243311B (en) | New frameworks for antibodies | |
| JP7760377B2 (ja) | タンパク質を多量体化する変異体ドメイン及びその分離 | |
| IL271128B1 (en) | New anti-3CD antibodies | |
| IL317013A (en) | Binding proteins are activated under limited conditions | |
| IL295729A (en) | Bispecific engineered anti-2her proteins, preparations containing them and their uses | |
| WO2013064701A2 (en) | Bispecific antibodies and methods for isolating same | |
| IL295749A (en) | Bispecific molecules binding gd2 and b7h2 and methods of use | |
| IL284317B1 (en) | Pseudofab-based multispecific binding proteins | |
| IL287291B (en) | A protein that binds to rgma and its use | |
| JP7123063B2 (ja) | 抗体ドメインの好ましい対形成 | |
| US20260078202A1 (en) | Orthogonal mutations for heterodimerization | |
| IL297847A (en) | Anti-pd-l1 antibody and its use | |
| IL270308B2 (en) | Anti-interferon gamma antibodies and their uses | |
| IL323768A (en) | Anti-cd28 x anti-trop2 antibodies | |
| CA3210307A1 (en) | Bispecific antibody | |
| IL271127B1 (en) | New anti-HSA antibodies | |
| IL323870A (en) | Antibodies against x cd28 and anti enpp3 | |
| IL310700A (en) | Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines | |
| IL298076A (en) | Multispecific antibodies | |
| IL321347A (en) | Fusion comprising anti-tau antibody and peptide and use thereof | |
| IL322940A (en) | Multivalent anti-spike protein binding molecules and their uses | |
| IL294714A (en) | Anti-nkp30 antibodies and methods of use |